It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The immunoprotective components control COVID-19 disease severity, as well as long-term adaptive immunity maintenance and subsequent reinfection risk discrepancies across initial COVID-19 severity, remain unclarified. Here, we longitudinally analyzed SARS-CoV-2-specific immune effectors during the acute infection and convalescent phases of 165 patients with COVID-19 categorized by severity. We found that early and robust SARS-CoV-2-specific CD4+ and CD8+ T cell responses ameliorate disease progression and shortened hospital stay, while delayed and attenuated virus-specific CD8+ T cell responses are prominent severe COVID-19 features. Delayed antiviral antibody generation rather than titer level associates with severe outcomes. Conversely, initial COVID-19 severity imprints the long-term maintenance of SARS-CoV-2-specific adaptive immunity, demonstrating that severe convalescents exhibited more sustained virus-specific antibodies and memory T cell responses compared to mild/moderate counterparts. Moreover, initial COVID-19 severity inversely correlates with SARS-CoV-2 reinfection risk. Overall, our study unravels the complicated interaction between temporal characteristics of virus-specific T cell responses and COVID-19 severity to guide future SARS-CoV-2 wave management.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 The First People’s Hospital of Yunnan province, The Affiliated Hospital of Kunming University of Science and Technology. Department of Respiratory and Critical Care Medicine, Kunming, China (GRID:grid.414918.1); Bioland, Guangzhou National Laboratory, Guangzhou, China (GRID:grid.508040.9) (ISNI:0000 0004 9415 435X)
2 Bioland, Guangzhou National Laboratory, Guangzhou, China (GRID:grid.508040.9) (ISNI:0000 0004 9415 435X); Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072)
3 The First People’s Hospital of Yunnan province, The Affiliated Hospital of Kunming University of Science and Technology. Department of Respiratory and Critical Care Medicine, Kunming, China (GRID:grid.414918.1)
4 The First People’s Hospital of Yunnan province, The Affiliated Hospital of Kunming University of Science and Technology. Department of Respiratory and Critical Care Medicine, Kunming, China (GRID:grid.414918.1); Bioland, Guangzhou National Laboratory, Guangzhou, China (GRID:grid.508040.9) (ISNI:0000 0004 9415 435X); Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072)